Novacyt S.A. Conversion of Loan Notes (6819N)

TIDMNCYT

RNS Number : 6819N

Novacyt S.A.

25 September 2019

Novacyt S.A.

("Novacyt" or the "Company")

Conversion of Loan Notes

Paris, France and Camberley, UK - 25 September 2019 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that, pursuant to the Convertible Bonds with Warrants Funding Programme announced on 26 April 2019, it has issued a tranche of new ordinary shares of EUR1/15 each ("Ordinary Shares") to Negma Group Limited following the receipt of conversion notices. Further details are set out below.

Conversion notices dated: 25 September 2019

 
 Number of Notes converted                   38 
 Conversion amount                           EUR95,000 
 Lowest VWAP during the 15 days preceding 
  the conversion notice                      EUR0.0725 
 Conversion price                            EUR0.0667 
 Number of shares issued                     1,425,000 
 

Application will be made for the 1,425,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on 1 October 2019. Admission of the new Ordinary Shares to trading on Euronext is expected to occur on or before 1 October 2019.

Total Voting Rights

Following Admission, the total number of ordinary shares in the Company is 57,119,754. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

- End -

For further information, please refer to www.novacyt.com or contact:

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

[phone]

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Jamie Spotswood (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

[phone]

FTI Consulting (International)

Brett Pollard / Victoria Foster Mitchell/ Mary Whittow

[phone]

[e-mail]/[e-mail]/ [e-mail]

FTI Consulting (France)

Arnaud de Cheffontaines / Astrid Villette

[phone] / [phone]

[e-mail] / [e-mail]

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

CONBSGDCXSDBGCU

(END) Dow Jones Newswires

September 25, 2019 10:46 ET (14:46 GMT)